BW-B 70C |
| Catalog No.GC10709 |
5-Lipoxygenase inhibitor,potent and selective
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 134470-38-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
BW-B 70C is a potent and selective inhibitor of 5-lipoxygenase [1].
5-lipoxygenase is an enzyme that transforms essential fatty acids (EFAs) into leukotrienes and is activated by 5-lipoxygenase activating protein (FLAP).
BW-B 70C is a potent and selective 5-lipoxygenase inhibitor. BW-B 70C had high potency and long duration in vivo and was considered as potential anti-asthma drug [1]. In sensitised guinea-pigs, BW B70C (2-50 mg/kg) inhibited bronchoconstriction induced by allergen in a dose-dependent way, which was consistent with the inhibitory activity of BW B70C against 5-lipoxygenase. Also, BW B70C (20 mg/kg) inhibited eosinophil infiltration by 67% [2]. In guinea-pigs, The 5-lipoxygenase inhibitor, BW B70C (30 mg/kg) inhibited leucocyte migration to the airways lumen, leukotriene C4 synthesis by alveolar macrophages and albumin microvascular leakage induced by endotoxin. However, BW B70C didn’t affect vascular leucocyte margination and the blood levels of secreted phospholipase A2 and TNF-α [3]. In a focal cerebral ischemia rat model, BW-B 70C improved neurological deficit scores and decreased infarctions. Also, BW-B 70C reduced 5-lipoxygenase (5-LOX) and inhibited inducible nitric oxide synthase (iNOS) expression through down-regulation of NF-κB [4].
References:
[1]. Payne AN, Jackson WP, Salmon JA, et al. Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl, 1991, 34: 189-199.
[2]. Yeadon M, Dougan FL, Petrovic A, et al. Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs. Agents Actions, 1993, 38(1-2): 8-18.
[3]. Bureau MF, De Castro CM, Cortese C, et al. 5-Lipoxygenase and endotoxin-induced microvascular albumin exchanges and leucocyte recruitment in guinea-pig lungs. Eur J Pharmacol, 1997, 324(1): 89-98.
[4]. Jatana M, Giri S, Ansari MA, et al. Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J Neuroinflammation, 2006, 3: 12.
| Cas No. | 134470-38-5 | SDF | |
| Chemical Name | (R,E)-1-(4-(3-(4-fluorophenoxy)phenyl)but-3-en-2-yl)-1-hydroxyurea | ||
| Canonical SMILES | FC1=CC=C(C=C1)OC2=CC(/C=C/[C@@H](C)N(C(N)=O)O)=CC=C2 | ||
| Formula | C17H17FN2O3 | M.Wt | 316.33 |
| Solubility | Limited solubility, soluble in DMSO or ethanol | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1613 mL | 15.8063 mL | 31.6126 mL |
| 5 mM | 0.6323 mL | 3.1613 mL | 6.3225 mL |
| 10 mM | 0.3161 mL | 1.5806 mL | 3.1613 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *